Introduction of 131631-89-5 :

Fuscoside (OPC-21268) is an orally effective, nonpeptide, vasopressin V1 receptor antagonist with an IC₅₀ of 0.4 μM. IC50 & Target: IC50: 0.4 μM (vasopressin V1)

Ki: 0.14 μM (vasopressin V1)^[1]

In Vitro: The concentration of Fuscoside (OPC-21268) that displaces 50% of specific AVP binding (IC ₅₀) is 0.4 μM for VI receptors and 100 μM for V2 receptors. The inhibition constant (K _i) of Fuscoside (OPC-21268) for V1 receptors (0.14 μM) ^[1]. In Vivo: Fuscoside (OPC-21268) competitively and specifically antagonizes pressor responses to AVP in vivo. Oral administration of Fuscoside (OPC-21268) (10 mg/kg) inhibits the vasoconstriction induced by exogenous AVP in a dose- and time-dependent manner and the effect lasts for more than 8 hours at 30 mg/kg ^[1]. Fuscoside (OPC-21268) predominantly exerts a protective effect in areas where the maximum amount of blood-brain barrier breakdown occurs, and it is effective in the treatment of cold-induced vasogenic brain edema. Fuscoside (OPC-21268) treatment at the dosages of 200 and 300 mg/kg significantly reduces brain water content in both hemispheres. Swelling of the traumatized hemispheres is also significantly reduced at 200 and 300 mg/kg dosages ^[2].